.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,723,340

« Back to Dashboard
Patent 6,723,340 protects GRALISE, GLUMETZA, and INVOKAMET XR, and is included in three NDAs. There have been zero Paragraph IV challenges on Gralise and Glumetza There are two tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has eleven patent family members in eight countries.

Summary for Patent: 6,723,340

Title: Optimal polymer mixtures for gastric retentive tablets
Abstract:Unit dosage form tablets for the delivery of pharmaceuticals are formed of the pharmaceutical dispersed in a solid unitary matrix that is formed of a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose. The combination offers unique benefits in terms of release rate control and reproducibility while allowing both swelling of the tablet to effect gastric retention and gradual disintegration of the tablet to clear the tablet from the gastrointestinal tract after release of the drug has occurred.
Inventor(s): Gusler; Gloria (Cupertino, CA), Berner; Bret (El Granada, CA), Chau; Mei (Sunnyvale, CA), Padua; Aimee (Daly City, CA)
Assignee: DepoMed, Inc. (Menlo Park, CA)
Application Number:10/029,134
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 15th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Depomed Inc
GRALISE
gabapentin
TABLET;ORAL022544-001Jan 28, 2011RXYes6,723,340► subscribeY
Depomed Inc
GRALISE
gabapentin
TABLET;ORAL022544-002Jan 28, 2011RXYes6,723,340► subscribeY
Santarus Inc
GLUMETZA
metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021748-001Jun 3, 2005RXNo6,723,340► subscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,723,340

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria536863► subscribe
Australia2002337974► subscribe
Canada2409999► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc